Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the United States FDA. As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety conce...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Yue Sun, Yanbo Yang, Zilan Wang, Fan Jiang, Zhouqing Chen, Zhong Wang
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2020-11-01
coleção:	Frontiers in Pharmacology
Assuntos:	meta-analysis new or enlarging T2 lesions gadolinium-enhancing lesions ozanimod relapsing-remitting multiple sclerosis annualized relapse rate
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2020.589146/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!